Soleno Therapeutics Inc (NASDAQ: SLNO) released top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for
Femasys Inc (NASDAQ: FEMY) shares surged after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a
Vapotherm Inc (NASDAQ: VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention
Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ: PHVS), noting that the company stands out as one of the players with their strategy to develop and advance oral therapeutic options in both the acute and prophylactic settings for hereditary angioedema (HAE).
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of Udenyca (pegfilgrastim-cbqv), solely due to an ongoing review of inspection
H.C. Wainwright initiated coverage on AngioDynamics Inc (NASDAQ: ANGO), noting that the company is debt-free and significantly undervalued compared to peers in a growing market.
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results at United